Allos Therapeutics, Inc.

210 articles about Allos Therapeutics, Inc.

• Allos Therapeutics, Inc. Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status

  5/26/2009

• Allos Therapeutics, Inc. Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at American Society of Clinical Oncology 2009

  5/15/2009

• Allos Therapeutics, Inc. to Present at the Eighth Annual JMP Securities Research Conference

  5/12/2009

• Allos Therapeutics, Inc. Reports First Quarter 2009 Financial Results

  5/6/2009

• Allos Therapeutics, Inc. to Report First Quarter 2009 Results on May 5, 2009

  4/29/2009

• Allos Therapeutics, Inc. to Present at the American Association for Cancer Research Annual Meeting 2009

  4/15/2009

• Allos Therapeutics, Inc. Announces Closing of Common Stock Offering

  4/6/2009

• Allos Therapeutics, Inc. Announces Pricing of Common Stock Offering

  3/31/2009

• Allos Therapeutics, Inc. to Present at the 4th Annual Citi Biotech Day

  3/26/2009

• Allos Therapeutics, Inc. Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

  3/25/2009

• Allos Therapeutics, Inc. Appoints David M. Stout to Its Board of Directors

  3/24/2009

• Allos Therapeutics, Inc.’s Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission

  3/17/2009

• Allos Therapeutics, Inc. Reports 2008 Results

  3/4/2009

• Allos Therapeutics, Inc. to Report 2008 Results on March 3, 2009

  2/27/2009

• Allos Therapeutics, Inc. Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma; Company Plans to Submit New Drug Application to FDA in First Half of 2009

  2/4/2009

• Allos Therapeutics, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference

  12/10/2008

• Allos Therapeutics, Inc. to Host Analyst and Investor Briefing on Monday, December 8, 2008

  12/3/2008

• Allos Therapeutics, Inc. Release: Four Pralatrexate (PDX) Studies to Be Presented at the 50th Annual Meeting of the American Society of Hematology

  11/10/2008

• Allos Therapeutics, Inc. Reports 2008 Third Quarter Results

  11/6/2008

• Allos Therapeutics, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

  11/4/2008